Advertisement
UK markets close in 2 hours 9 minutes

  • FTSE 100

    8,118.20
    +39.34 (+0.49%)
     

  • FTSE 250

    19,789.17
    +187.19 (+0.95%)
     

  • AIM

    754.71
    +1.59 (+0.21%)
     

  • GBP/EUR

    1.1670
    +0.0013 (+0.11%)
     

  • GBP/USD

    1.2504
    -0.0007 (-0.06%)
     

  • Bitcoin GBP

    51,065.86
    +748.34 (+1.49%)
     

  • CMC Crypto 200

    1,385.18
    -11.36 (-0.81%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CRUDE OIL

    84.24
    +0.67 (+0.80%)
     

  • GOLD FUTURES

    2,359.10
    +16.60 (+0.71%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,075.17
    +157.89 (+0.88%)
     

  • CAC 40

    8,058.36
    +41.71 (+0.52%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

A Strong Pipeline of Drugs Bodes Well for Radius Health

Kenneth Smith
Updated
A Strong Pipeline of Drugs Bodes Well for Radius Health

The drug candidates in Radius Health’s (RDUS) pipeline include an investigational abaloparatide transdermal patch for possible use in treating women with postmenopausal osteoporosis. Another candidate is the investigational drug elacestrant (or RAD1901), which is a selective estrogen receptor degrader for the treatment of hormone receptor-positive breast cancer and the treatment of vasometer symptoms in postmenopausal women. The pipeline also includes the investigational drug RAD140, a nonsteroidal selective androgen receptor modulator, for its potential use in treating hormone receptor-positive breast cancer.

Continue reading